Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Paeds Topicsclinical-pharmacology-and-therapeutics

Paeds · clinical-pharmacology-and-therapeutics

Chemotherapy and supportive pharmacology

Also known as Cytotoxic chemotherapy in children · Antiemetics in paediatric oncology · G-CSF and pegfilgrastim in children · Dexrazoxane cardioprotection · Palifermin for mucositis · Anthracycline extravasation management

A fellowship approach to chemotherapy and supportive pharmacology in children covering the cytotoxic drug classes and their organ-specific toxicities, the antiemetic ladder built on 5-HT3 antagonists (ondansetron), the NK1 antagonist aprepitant and dexamethasone for chemotherapy-induced nausea and vomiting, the colony-stimulating factors filgrastim and pegfilgrastim for febrile neutropenia prophylaxis, palifermin (keratinocyte growth factor) for oral mucositis after stem-cell transplant conditioning, dexrazoxane for anthracycline cardioprotection and extravasation, and the non-negotiable rule that vincristine is given intravenously and never by the intrathecal route.

medium11 referencesUpdated 17 July 202620 min readVerification in progress

Practise this topic

  • SAQ
  • Viva
  • Case

Your progress

Saved on this device.

Practise this topic

  • Short-answer question1
  • Viva station1
  • Clinical case1

Target exams

RACP General PaediatricsRACP DWERACP DCERCPCH Progress+MRCPCH TheoryMRCPCH ClinicalABP General PediatricsACGME PediatricsRCPSC Pediatrics

Red flags

  • Vincristine prepared or delivered by the intrathecal route — a uniformly fatal administration error that must never occur
  • An anthracycline such as doxorubicin or daunorubicin given without a documented cumulative-dose record and cardiac surveillance plan
  • Anthracycline extravasation managed with cold compresses rather than dexrazoxane — cold worsens vinca injury and cold is wrong for anthracycline
  • Ondansetron given in large intravenous doses without awareness of dose-related QT prolongation
  • A child on chemotherapy presenting with febrile neutropenia treated as a routine viral illness rather than a medical emergency
  • Dexrazoxane withheld because of an out-of-date fear of secondary malignancy when the child is receiving a high cumulative anthracycline dose

Life stages

infanttoddlerpreschoolschool-ageadolescentyoung-adult-transition

Care settings

outpatientwarded-acutepicutelehealth

Clinical exam formats

written-only

Board mappings

  • General and Community Paediatrics
  • Allergy and Immunology
  • Current 2026 PREP curriculum — Learning Objective: Safe prescribing and medication management in infants, children and young people
  • Current 2026 PREP curriculum — Learning Objective 2.2.1: Recognise, prioritise and manage an acutely ill infant, child or young person
  • Renewed curriculum for first-year trainees from 2027 — Learning goal 6: Clinical management – essential general paediatrics
  • Renewed curriculum for first-year trainees from 2027 — Learning goal 9: Quality and safety, including medication safety
  • Clinical Applications
  • Medical Sciences
  • Long Cases
  • Short Cases
  • 4. Professional skills and knowledge: Patient management
  • 7. Patient safety, including safe prescribing
  • 8. Quality improvement and patient safety
  • General Paediatrics: Understands cytotoxic chemotherapy classes, supportive care medicines, and the non-negotiable vincristine-intrathecal safety rule
  • Foundation of Practice (FOP)
  • Theory and Science (TAS)
  • Applied Knowledge in Practice (AKP)
  • Clinical
  • History
  • Communication
  • General Pediatrics Content Outline — Domain 10: Principles of Pharmacology and Medication Management
  • General Pediatrics Content Outline — Universal Task 4: Management and Treatment
  • General Pediatrics Content Outline — Universal Task 2: Health Maintenance
  • Systems-Based Practice 2: Coordinated chronic disease care
  • Patient Safety/Quality Improvement 1: Medication Safety
  • Medical Knowledge 2: Diagnostic and Therapeutic Decision Making
  • Medical Expert
  • Collaborator
  • Pediatrics: Core EPA #5 — Recommending and Initiating Pharmacologic Interventions
On this page
Study tools

Your progress

Saved on this device.

Practise this topic

  • Short-answer question1
  • Viva station1
  • Clinical case1

Target exams

RACP General PaediatricsRACP DWERACP DCERCPCH Progress+MRCPCH TheoryMRCPCH ClinicalABP General PediatricsACGME PediatricsRCPSC Pediatrics

Red flags

  • Vincristine prepared or delivered by the intrathecal route — a uniformly fatal administration error that must never occur
  • An anthracycline such as doxorubicin or daunorubicin given without a documented cumulative-dose record and cardiac surveillance plan
  • Anthracycline extravasation managed with cold compresses rather than dexrazoxane — cold worsens vinca injury and cold is wrong for anthracycline
  • Ondansetron given in large intravenous doses without awareness of dose-related QT prolongation
  • A child on chemotherapy presenting with febrile neutropenia treated as a routine viral illness rather than a medical emergency
  • Dexrazoxane withheld because of an out-of-date fear of secondary malignancy when the child is receiving a high cumulative anthracycline dose

Life stages

infanttoddlerpreschoolschool-ageadolescentyoung-adult-transition

Care settings

outpatientwarded-acutepicutelehealth

Clinical exam formats

written-only

Board mappings

  • General and Community Paediatrics
  • Allergy and Immunology
  • Current 2026 PREP curriculum — Learning Objective: Safe prescribing and medication management in infants, children and young people
  • Current 2026 PREP curriculum — Learning Objective 2.2.1: Recognise, prioritise and manage an acutely ill infant, child or young person
  • Renewed curriculum for first-year trainees from 2027 — Learning goal 6: Clinical management – essential general paediatrics
  • Renewed curriculum for first-year trainees from 2027 — Learning goal 9: Quality and safety, including medication safety
  • Clinical Applications
  • Medical Sciences
  • Long Cases
  • Short Cases
  • 4. Professional skills and knowledge: Patient management
  • 7. Patient safety, including safe prescribing
  • 8. Quality improvement and patient safety
  • General Paediatrics: Understands cytotoxic chemotherapy classes, supportive care medicines, and the non-negotiable vincristine-intrathecal safety rule
  • Foundation of Practice (FOP)
  • Theory and Science (TAS)
  • Applied Knowledge in Practice (AKP)
  • Clinical
  • History
  • Communication
  • General Pediatrics Content Outline — Domain 10: Principles of Pharmacology and Medication Management
  • General Pediatrics Content Outline — Universal Task 4: Management and Treatment
  • General Pediatrics Content Outline — Universal Task 2: Health Maintenance
  • Systems-Based Practice 2: Coordinated chronic disease care
  • Patient Safety/Quality Improvement 1: Medication Safety
  • Medical Knowledge 2: Diagnostic and Therapeutic Decision Making
  • Medical Expert
  • Collaborator
  • Pediatrics: Core EPA #5 — Recommending and Initiating Pharmacologic Interventions
The fellowship answer

Chemotherapy and supportive pharmacology in children pair each cytotoxic drug class with the supportive medicine that prevents its characteristic harm. The anthracyclines doxorubicin and daunorubicin kill cancer cells but injure the myocardium, and dexrazoxane — an intracellular iron chelator given before the anthracycline — protects the heart and also rescues anthracycline extravasation. The vinca alkaloids block microtubules and cause neurotoxicity, and vincristine must travel by the intravenous route only — into the cerebrospinal fluid it is uniformly fatal, the single most dreaded chemotherapy administration error. Chemotherapy-induced nausea and vomiting rise on a ladder: the 5-HT3 antagonist ondansetron, the NK1 antagonist aprepitant, and dexamethasone are combined for the highly emetogenic regimens. Febrile neutropenia, the great killer of the myelosuppressed child, is prevented with the colony-stimulating factors filgrastim and the long-acting pegfilgrastim. And the severe oral mucositis that follows stem-cell transplant conditioning is reduced by palifermin, a keratinocyte growth factor. State the toxicity, name its antidote, and protect the route — that is the spine of safe paediatric oncology pharmacology.

[1][6][9]

Overview & Definition

Picture an eight-year-old receiving doxorubicin for acute lymphoblastic leukaemia whose echocardiogram is tracked cycle by cycle, a six-year-old on cisplatin who vomits for three days after each infusion, and a ten-year-old the morning after stem-cell transplant conditioning whose mouth is so sore he cannot swallow his own saliva. Each child is living a cytotoxic toxicity, and each one has a supportive medicine built to prevent or treat it. The general paediatrician rarely prescribes the cytotoxic agent, but shares the surveillance, the febrile-neutropenia front door, and the safety culture that keeps the routes right. [1] [11]

Give the examiner one sentence

Chemotherapy and supportive pharmacology in children means matching each cytotoxic drug class to the supportive medicine that prevents its characteristic harm — dexrazoxane for anthracycline cardiotoxicity, ondansetron with aprepitant and dexamethasone for emesis, filgrastim or pegfilgrastim for febrile neutropenia, palifermin for mucositis — while holding the non-negotiable rule that vincristine is intravenous and never intrathecal. Name the toxicity, name the antidote, and protect the route. [6] [10]

Two ideas carry the whole topic. The first is the toxicity-to-antidote pairing: every cytotoxic class has a predictable organ injury, and modern paediatric oncology pairs each one with a supportive drug that blunts the injury without abolishing the anti-cancer effect. The second is the route-safety culture: the cytotoxics are among the most dangerous drugs to administer, and the vincristine-intrathecal catastrophe is the cautionary tale that drives minibag dilution, separate intrathecal preparation times, and double-independent checks. [9] [11]

From the cytotoxic plan to the supported child

  1. 1

    1 · Know the drug and its toxicity

    Identify the cytotoxic class and the organ it injures — anthracycline to the heart, vinca to nerves, platinum to ears and kidneys, antimetabolite to marrow.

  2. 2

    2 · Match the supportive medicine

    Pair the toxicity with its antidote — dexrazoxane, antiemetics, colony-stimulating factors, palifermin, hydration and rasburicase as indicated.

  3. 3

    3 · Protect the route

    Confirm vincristine is intravenous only and never prepared with intrathecal drugs; apply independent checks and minibag dilution.

  4. 4

    4 · Plan the surveillance

    Track cumulative anthracycline dose with echocardiography and troponin, blood counts for neutropenia, and growth and development throughout.

  5. 5

    5 · Hold the front door

    Treat the febrile neutropenic child as a medical emergency: cultures and empirical antibiotics within the hour, never as a routine viral illness.

[6] [7]
Paediatrics Fellowship Pro

Continue reading

You have read the opening of this topic. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship library.

Sign in to continueSee pricing
References11ShowHide
  1. [1]Lipshultz SE; Rifai N; Dalton VM; Levy DE; Silverman LB; Lipsitz SR The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia The New England journal of medicine, 2004.PMID 15247354
  2. [2]Barry EV; Vrooman LM; Dahlberg SE; Neuberg DS; Asselin BL; Athale UH Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane Journal of clinical oncology, 2008.PMID 18309945
  3. [3]Lipshultz SE; Miller TL; Scully RE; Lipsitz SR; Rifai N; Silverman LB Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes Journal of clinical oncology, 2012.PMID 22370326
  4. [4]Spielberger R; Stiff P; Bensinger W; Gentile T; Weisdorf D; Kewalramani T Palifermin for oral mucositis after intensive therapy for hematologic cancers The New England journal of medicine, 2004.PMID 15602019
  5. [5]Kang HJ; Loftus S; Taylor A; DiCristina C; Green S; Zwaan CM Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial The Lancet. Oncology, 2015.PMID 25770814
  6. [6]Dupuis LL; Sung L; Molassiotis A; Orsey AD; Tissing W; van de Wetering M 2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children Supportive care in cancer, 2017.PMID 27565788
  7. [7]Smith TJ; Khatcheressian J; Lyman GH; Ozer H; Armitage JO; Balducci L 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline Journal of clinical oncology, 2006.PMID 16682719
  8. [8]Spunt SL; Irving H; Frost J; Sender L; Guo M; Yang BB Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients Journal of clinical oncology, 2010.PMID 20142595
  9. [9]Mouridsen HT; Langer SW; Buter J; Eidtmann H; Rosti G; de Wit M Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies Annals of oncology, 2007.PMID 17185744
  10. [10]van Dalen EC; Caron HN; Dickinson HO; Kremer LC Cardioprotective interventions for cancer patients receiving anthracyclines Cochrane database of systematic reviews, 2011.PMID 21678342
  11. [11]DeVine A; Landier W; Hudson MM; Constine LS; Bhatia S; Armenian SH The Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers: A Review JAMA oncology, 2025.PMID 39976936

Test yourself

Practise what you just read

  • SAQ
  • Viva
  • Case
Paediatrics Fellowship Pro

$29/ monthor $279 / year

The complete Paediatrics Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousCardiovascular medicines in childrenclinical-pharmacology-and-therapeuticsNextComplementary, alternative and traditional medicinesclinical-pharmacology-and-therapeutics